Idioma:

Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)

Marre, M. ; Shaw, J. ; Brändle, M. ; Bebakar, W. M. W. ; Kamaruddin, N. A. ; Strand, J. ; Zdravkovic, M. ; Le Thi, T. D. ; Colagiuri, S.

Diabetic medicine, 2009-03, Vol.26 (3), p.268-278 [Periódico revisado por pares]

Oxford, UK: Blackwell Publishing Ltd

Texto completo disponível

Citações Citado por

Enviar para

Título:
Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)
Autor: Marre, M. ; Shaw, J. ; Brändle, M. ; Bebakar, W. M. W. ; Kamaruddin, N. A. ; Strand, J. ; Zdravkovic, M. ; Le Thi, T. D. ; Colagiuri, S.
Assuntos: Aged ; Biological and medical sciences ; Blood Glucose - drug effects ; Body Weight - drug effects ; Diabetes Mellitus, Type 2 - blood ; Diabetes Mellitus, Type 2 - drug therapy ; Diabetes. Impaired glucose tolerance ; dipeptidyl peptidase-4 ; Double-Blind Method ; Drug Therapy, Combination ; Endocrine pancreas. Apud cells (diseases) ; Endocrinopathies ; Etiopathogenesis. Screening. Investigations. Target tissue resistance ; Feeding. Feeding behavior ; Female ; Fundamental and applied biological sciences. Psychology ; Glucagon-Like Peptide 1 - administration & dosage ; Glucagon-Like Peptide 1 - analogs & derivatives ; glucagon-like peptide-1 receptor agonist ; Humans ; Hypoglycemia - blood ; Hypoglycemia - drug therapy ; Hypoglycemic Agents - administration & dosage ; incretin ; insulinotropic ; Male ; Medical sciences ; Middle Aged ; Original ; Sulfonylurea Compounds - administration & dosage ; thiazolidinedione ; Thiazolidinediones - administration & dosage ; Vertebrates: anatomy and physiology, studies on body, several organs or systems ; Vertebrates: endocrinology
É parte de: Diabetic medicine, 2009-03, Vol.26 (3), p.268-278
Notas: ArticleID:DME2666
istex:5D1C5E0A9AA3323713F8940A437C40DABC0E7835
ark:/67375/WNG-00VZ70GK-R
Re‐use of this article is permitted in accordance with the Creative Commons Deed, Attribution 2.5, which does not permit commercial exploitation.
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-News-2
ObjectType-Feature-3
content type line 23
Re-use of this article is permitted in accordance with the Creative Commons Deed, Attribution 2.5, which does not permit commercial exploitation.
Descrição: Aim To compare the effects of combining liraglutide (0.6, 1.2 or 1.8 mg/day) or rosiglitazone 4 mg/day (all n ≥ 228) or placebo (n = 114) with glimepiride (2–4 mg/day) on glycaemic control, body weight and safety in Type 2 diabetes. Methods In total, 1041 adults (mean ± sd), age 56 ± 10 years, weight 82 ± 17 kg and glycated haemoglobin (HbA1c) 8.4 ± 1.0% at 116 sites in 21 countries were stratified based on previous oral glucose‐lowering mono : combination therapies (30 : 70%) to participate in a five‐arm, 26‐week, double‐dummy, randomized study. Results Liraglutide (1.2 or 1.8 mg) produced greater reductions in HbA1c from baseline, (−1.1%, baseline 8.5%) compared with placebo (+0.2%, P < 0.0001, baseline 8.4%) or rosiglitazone (−0.4%, P < 0.0001, baseline 8.4%) when added to glimepiride. Liraglutide 0.6 mg was less effective (−0.6%, baseline 8.4%). Fasting plasma glucose decreased by week 2, with a 1.6 mmol/l decrease from baseline at week 26 with liraglutide 1.2 mg (baseline 9.8 mmol/l) or 1.8 mg (baseline 9.7 mmol/l) compared with a 0.9 mmol/l increase (placebo, P < 0.0001, baseline 9.5 mmol/l) or 1.0 mmol/l decrease (rosiglitazone, P < 0.006, baseline 9.9 mmol/l). Decreases in postprandial plasma glucose from baseline were greater with liraglutide 1.2 or 1.8 mg [−2.5 to −2.7 mmol/l (baseline 12.9 mmol/l for both)] compared with placebo (−0.4 mmol/l, P < 0.0001, baseline 12.7 mmol/l) or rosiglitazone (−1.8 mmol/l, P < 0.05, baseline 13.0 mmol/l). Changes in body weight with liraglutide 1.8 mg (−0.2 kg, baseline 83.0 kg), 1.2 mg (+0.3 kg, baseline 80.0 kg) or placebo (−0.1 kg, baseline 81.9 kg) were less than with rosiglitazone (+2.1 kg, P < 0.0001, baseline 80.6 kg). Main adverse events for all treatments were minor hypoglycaemia (< 10%), nausea (< 11%), vomiting (< 5%) and diarrhoea (< 8%). Conclusions Liraglutide added to glimepiride was well tolerated and provided improved glycaemic control and favourable weight profile.
Editor: Oxford, UK: Blackwell Publishing Ltd
Idioma: Inglês

Links

Voltar para lista de resultados

Anterior Resultado 7 Avançar Ir para próxima página

Realização: Logos de Redes Sociais:

Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)

Marre, M. ; Shaw, J. ; Brändle, M. ; Bebakar, W. M. W. ; Kamaruddin, N. A. ; Strand, J. ; Zdravkovic, M. ; Le Thi, T. D. ; Colagiuri, S.

Oxford, UK: Blackwell Publishing Ltd

Buscando em bases de dados remotas. Favor aguardar.